136 related articles for article (PubMed ID: 10415743)
1. Matrix metalloproteinase inhibition. From the Jurassic to the third millennium.
Woessner JF
Ann N Y Acad Sci; 1999 Jun; 878():388-403. PubMed ID: 10415743
[TBL] [Abstract][Full Text] [Related]
2. Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase.
Bigg HF; Morrison CJ; Butler GS; Bogoyevitch MA; Wang Z; Soloway PD; Overall CM
Cancer Res; 2001 May; 61(9):3610-8. PubMed ID: 11325829
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinases and their inhibition in periodontal treatment.
Ryan ME; Ramamurthy S; Golub LM
Curr Opin Periodontol; 1996; 3():85-96. PubMed ID: 8624573
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases and their inhibitors in gastric cancer.
Murray GI; Duncan ME; Arbuckle E; Melvin WT; Fothergill JE
Gut; 1998 Dec; 43(6):791-7. PubMed ID: 9824606
[TBL] [Abstract][Full Text] [Related]
5. Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-alpha receptors in a human colon adenocarcinoma (Colo 205) cell line.
Lombard MA; Wallace TL; Kubicek MF; Petzold GL; Mitchell MA; Hendges SK; Wilks JW
Cancer Res; 1998 Sep; 58(17):4001-7. PubMed ID: 9731514
[TBL] [Abstract][Full Text] [Related]
6. Design strategies for the identification of MMP-13 and Tace inhibitors.
Skotnicki JS; DiGrandi MJ; Levin JI
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):742-59. PubMed ID: 14579524
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in loose artificial hip joints.
Takagi M; Santavirta S; Ida H; Ishii M; Mandelin J; Konttinen YT
Clin Orthop Relat Res; 1998 Jul; (352):35-45. PubMed ID: 9678031
[TBL] [Abstract][Full Text] [Related]
8. Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.
Scozzafava A; Supuran CT
J Med Chem; 2000 May; 43(9):1858-65. PubMed ID: 10794702
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines.
Afzal S; Lalani el-N ; Foulkes WD; Boyce B; Tickle S; Cardillo MR; Baker T; Pignatelli M; Stamp GW
Lab Invest; 1996 Feb; 74(2):406-21. PubMed ID: 8780160
[TBL] [Abstract][Full Text] [Related]
11. E. coli expression of TIMP-4 and comparative kinetic studies with TIMP-1 and TIMP-2: insights into the interactions of TIMPs and matrix metalloproteinase 2 (gelatinase A).
Troeberg L; Tanaka M; Wait R; Shi YE; Brew K; Nagase H
Biochemistry; 2002 Dec; 41(50):15025-35. PubMed ID: 12475252
[TBL] [Abstract][Full Text] [Related]
12. Complex roles of tissue inhibitors of metalloproteinases in cancer.
Jiang Y; Goldberg ID; Shi YE
Oncogene; 2002 Mar; 21(14):2245-52. PubMed ID: 11948407
[TBL] [Abstract][Full Text] [Related]
13. Paradoxical stimulation of matrix metalloproteinase-9 expression in HT1080 cells by a broad-spectrum hydroxamate-based matrix metalloproteinase inhibitor.
Maquoi E; Munaut C; Colige A; Lambert C; Frankenne F; Noël A; Grams F; Krell HW; Foidart JM
Ann N Y Acad Sci; 1999 Jun; 878():744-6. PubMed ID: 10415825
[No Abstract] [Full Text] [Related]
14. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
Yamamoto M; Tsujishita H; Hori N; Ohishi Y; Inoue S; Ikeda S; Okada Y
J Med Chem; 1998 Apr; 41(8):1209-17. PubMed ID: 9548812
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of cyclic inhibitors of matrix metalloproteinases and TNF-alpha production.
Xue CB; He X; Roderick J; DeGrado WF; Cherney RJ; Hardman KD; Nelson DJ; Copeland RA; Jaffee BD; Decicco CP
J Med Chem; 1998 May; 41(11):1745-8. PubMed ID: 9599225
[No Abstract] [Full Text] [Related]
16. Secretion of matrix metalloproteinase-2, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases into the intrauterine compartments during early pregnancy.
Riley SC; Leask R; Chard T; Wathen NC; Calder AA; Howe DC
Mol Hum Reprod; 1999 Apr; 5(4):376-81. PubMed ID: 10321811
[TBL] [Abstract][Full Text] [Related]
17. Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells.
Duivenvoorden WC; Hirte HW; Singh G
Invasion Metastasis; 1997; 17(6):312-22. PubMed ID: 9949290
[TBL] [Abstract][Full Text] [Related]
18. Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
Wada CK; Holms JH; Curtin ML; Dai Y; Florjancic AS; Garland RB; Guo Y; Heyman HR; Stacey JR; Steinman DH; Albert DH; Bouska JJ; Elmore IN; Goodfellow CL; Marcotte PA; Tapang P; Morgan DW; Michaelides MR; Davidsen SK
J Med Chem; 2002 Jan; 45(1):219-32. PubMed ID: 11754593
[TBL] [Abstract][Full Text] [Related]
19. Insights into MMP-TIMP interactions.
Bode W; Fernandez-Catalan C; Grams F; Gomis-Rüth FX; Nagase H; Tschesche H; Maskos K
Ann N Y Acad Sci; 1999 Jun; 878():73-91. PubMed ID: 10415721
[TBL] [Abstract][Full Text] [Related]
20. T lymphocytes activated by persistent viral infection differentially modify the expression of metalloproteinases and their endogenous inhibitors, TIMPs, in human astrocytes: relevance to HTLV-I-induced neurological disease.
Giraudon P; Szymocha R; Buart S; Bernard A; Cartier L; Belin MF; Akaoka H
J Immunol; 2000 Mar; 164(5):2718-27. PubMed ID: 10679113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
